Rockwell Medical Inc (NASDAQ:RMTI) was the recipient of unusually large options trading on Thursday. Traders bought 3,054 put options on the company. This represents an increase of approximately 3,815% compared to the typical daily volume of 78 put options.
Hedge funds have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Rockwell Medical in the 3rd quarter valued at $107,000. PNC Financial Services Group Inc. boosted its holdings in shares of Rockwell Medical by 1,725.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 15,245 shares of the company’s stock valued at $121,000 after purchasing an additional 14,410 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Rockwell Medical by 38.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 19,843 shares of the company’s stock valued at $157,000 after purchasing an additional 5,500 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Rockwell Medical in the 2nd quarter valued at $182,000. Finally, National Asset Management Inc. acquired a new stake in shares of Rockwell Medical in the 2nd quarter valued at $203,000. 21.26% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on RMTI shares. Zacks Investment Research upgraded Rockwell Medical from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research note on Wednesday, October 25th. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Friday, December 15th.
Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Wednesday, November 8th. The company reported ($0.10) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.10). The firm had revenue of $14.63 million for the quarter, compared to the consensus estimate of $13.33 million. Rockwell Medical had a negative return on equity of 47.93% and a negative net margin of 34.57%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.09) EPS. equities research analysts predict that Rockwell Medical will post -0.44 earnings per share for the current year.
WARNING: “Rockwell Medical Sees Unusually High Options Volume (RMTI)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/21/rockwell-medical-sees-unusually-high-options-volume-rmti.html.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.